Showing results (511-520 of 654) with videos related to
Sort By:
Pageof 66
The New England Journal of Medicine|June 5, 2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesRajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, et al.The Lancet. Diabetes & Endocrinology|December 18, 2020
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trialDavid C Wheeler, Bergur V Stefánsson, Niels Jongs, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 7, 2025
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristicsRajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, et al.Journal of Hypertension|September 3, 2010
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individualsChristian Delles, Eric Schiffer, Constantin von Zur Muhlen, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.International Journal of Molecular Sciences|May 13, 2026
Intra-Individual Variability of Urinary EGF and Clusterin, and Effect of Frozen Storage on Stability: Results from UVALIDErik Moedt, Rémon Vos, Wenjun Ju, et al.Diabetes, Obesity & Metabolism|June 15, 2026
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE TrialJanet B McGill, Jennifer B Green, Hiddo J L Heerspink, et al.Eclinicalmedicine|August 13, 2021
Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trialJens Christian Laursen, Niels Søndergaard-Heinrich, Joana Mendes Lopes de Melo, et al.European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.Pageof 66